Study S002628

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07685808
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 360
Start: 2026-07-28
Primary completion: 2028-01-21
Lead sponsor: Regeneron Pharmaceuticals
Conditions: Overweight or Obesity
Interventions: DRUG:Olatorepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Occurrence of Treatment-Emergent Adverse Events (TEAEs) [Up to approximately 60 weeks]
Severity of TEAEs [Up to approximately 60 weeks]
Percent change in body weight [From baseline to week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.